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involved in liver regeneration has been debated for several dec-
ades. It has long been known, as highlighted by the ancient myth
of Prometheus, that the normal liver has an amazing capacity to
regenerate after partial resection. In 1962, a convincing demon-
stration was published showing that mature differentiated hepa-
tocytes alone were involved in this process [4]. However, when
hepatocyte division is impaired, the involvement of stem cells is
mandatory for correct liver regeneration. More than 50 years
ago, the group of Farber revealed the existence of a new type of
epithelial cells, the oval cells, in the liver of rats treated with
hepatocarcinogens blocking hepatocyte division [3]. These oval
cells were bipotent progenitors able to give rise to both hepato-
cytes and biliary cells [2]. Although the fate of these new hepatic
stem cells was intensively studied, the exact location of the histo-
logical niche where they remain in a quiescent state is still not
clearly deﬁned. In 1999, a provocative study by Petersen et al.
unveiled the ability of bone marrow to serve as a potential source
of oval cells and subsequently, the transdifferentiation of bone
marrow stem cells to the hepatic lineage was reported in a num-
ber of studies [9]. Mesenchymal stem cells from bone marrow
were also identiﬁed as a potential source of hepatic progenitors
and, more recently, convincing evidence that adipose tissue-
derived mesenchymal stem cells (AT-MSCs) were also a source
of hepatocytes was reported [1,10]. These results have given rise
to much controversy and some investigators have claimed that
transdifferentiation of bone marrow stem cells into hepatocytes
was actually the result of a cell fusion process [12,13]. Nonethe-
less, and whatever the mechanism involved, it seems now well
documented that mesenchymal stem cells may undergo hepatic
differentiation whether in vitro or in vivo. Because such higly
replicative stem cells are readily isolated from adipose tissue,
which is easily harvested in most patients, it becomes theoreti-Journal of Hepatology 20
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oprotein; MoMULV, Moloney Murine Leukemia virus.cally possible to cultivate and amplify large amounts of autolo-
gous cells that can be used for cell therapy of liver failure.
In their present study, Li et al. have built up on these premises
and they evaluated whether AT-MSCs may be used as a cell ther-
apy platform for ex vivo gene therapy of liver inherited disorders
as well [6]. They prepared AT-MSCs from peritoneal tissue of
adult male mice. They veriﬁed that they were able to differentiate
these cells along adipogenic or osteogenic lineages. They then
comparatively evaluated the efﬁciency of different recombinant
adeno-associated virus (AAV) serotypes with a single stranded
or a double stranded genome to transduce AT-MSCs using the
human alpha 1-antitrypsin (AAT) cDNA as a reporter gene. Using
a high multiplicity of infection, AAV from serotype 1 was by
far the most potent serotype. However, at odds with previous
studies of AAV-mediated gene transfer in vivo [7], single strand
AAV vectors were more efﬁcient than their double strand coun-
terpart. This may be explained by the fact that AT-MSCs were
transduced in vitro. Also, a CMV promoter was used in double
strand vectors whereas the CB promoter drove expression of
human AAT in single strand vectors. After transduction, AT-MSCs
were re-implanted in female recipients immediately after a two
third partial hepatectomy. Furthermore, the animals were pre-
treated with monocrotaline. The partial hepatectomy was aimed
at stimulating liver regeneration and monocrotaline is a pyrrolizi-
dine alkaloid that blocks hepatocyte division. In this setting,
mature hepatocytes are unable to divide and there is a strong
selective growth advantage for injected cells that have not been
intoxicated by monocrotaline. After 8 weeks, recipient mice were
sacriﬁced. Immunohistochemical detection of human AAT
revealed that 20% of the cells in the liver parenchyma were from
donor origin. The human AAT positive cells also expressed mouse
albumin indicating that they were differentiated hepatocytes.
Unfortunately, the authors were not able to quantitate the
amount of Y positive cells in the liver. Therefore, it is not possible
to discriminate whether co-expression of human AAT cDNA and
mouse albumin resulted from transdifferentiation of AT-MSCs
in hepatocytes or from cell fusion between stem cells and hepa-
tocytes. The human AAT serum level was in the range of 100–
250 ng/ml. This value corresponds to less than 0.1% of the normal
value and is surprisingly lower than the value expected from the
number of human AAT-transduced hepatocytes present in the
liver (20%). This may be explained by a poor activity of the CB11 vol. 54 j 851–852
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promoter in hepatocytes in vivo. Also, it cannot be excluded that
when transduced AT-MScs differentiated into hepatocytes, they
synthesized both human and mouse AAT and that a competition
of both forms in the secretory pathway resulted in lower
amounts of the human protein in the serum.
A very encouraging ﬁnding for future clinical applications was
the absence of immune response to the transgene product.
Indeed, many gene therapy strategies are hampered by the induc-
tion of humoral or cytotoxic immune responses that occur after
gene-transfer mediated expression of non-self proteins. Such an
absence of immune reaction may be related to the defective
priming of antigen presenting cells after implantation of ex vivo
transduced cells or to the known tolerogenic capacity of mesen-
chymal cells [11]. It may also result from direct tolerance after
selective AAV-mediated gene transfer to hepatocytes as already
observed [8]. Finally, using GFP as a marker gene, the authors
analyzed the dissemination of injected cells in the whole body.
By using immunostaining, GFP positive cells were detected only
in spleen, lung, and bone marrow. These GFP positive cells were
not further characterized. Although immunostaining is less sensi-
tive than other methods such as PCR, the absence of engraftment
in a large number of organs is promising for future cell therapy
protocols.
These data open new ways that deserve consideration for
future clinical application for the treatment of liver inherited dis-
eases. Indeed, a major bottleneck for liver directed cell therapy
resides in the need for a huge amount of cells that should be
infused to reach a therapeutic threshold. The shortage of liver
graft is a strong limitation in the preparation of large batches of
allogenic hepatocytes. On the other hand, the use of embryonic
stem cells or induced pluripotent stem cells is still limited by
considerations related to ethics or biosafety. Therefore, the dem-
onstration that autologous mesenchymal cells obtained from fat
and transduced ex vivo may result in long term expression of
the transgene is promising.
However, some issues remain to be addressed in future stud-
ies. First, these results were obtained in animals that were treated
with monocrotaline to stop hepatocyte division and the clinical
application of this strategy is not conspicuous. With the excep-
tion of inherited diseases in which a strong growth advantage
for corrected cells is present, such as type 1 tyrosinemia, other
strategies should be evaluated to harness AT-MSCs with some
selective advantage to efﬁciently repopulate the diseased liver.
Second, the authors used recombinant AAV vectors that are not
integrative vectors. Although transgene was still expressed after
8 weeks, permanent expression cannot be guaranteed unless
integration of the recombinant genome in the corrected cell is
achieved. This is particularly true when transduced cells are com-
mitted to further division. Therefore, comparison of the efﬁcacy
of a panel of gene transfer vectors, whether integrative [such as
lentiviral vectors] or not, to achieve permanent correction in a
regenerating liver should be considered.
The ﬁrst clinical trial for gene therapy of a liver inherited dis-
order was carried out 20 years ago by the group of Jim Wilson in
Philadelphia [5]. It involved the harvest and culture of billions of852 Journal of Hepatology 201hepatocytes from LDL receptor deﬁcient patients. The cells were
transduced with MoMULV retroviral vectors and infused back
to patients via the portal vein. Although the procedure was safe
it did not yield therapeutic results and the trial demonstrated
that the efﬁciency of the vector as well as the handling of large
amounts of cells both were major limitations to widespread clin-
ical use. Twenty years later, the quality of the vectors has greatly
improved. Similarly, the availability of diverse sources of hepatic
stem cells obviates the need to perform a partial hepatectomy to
get the cells to be corrected. It is not overly optimistic to think
that liver gene therapy, either using an ex vivo or an in vivo strat-
egy, is on the verge of a new era, provided that the biosafety of
the procedure is fully validated to reach the high standards
required by regulatory agencies.Conﬂict of interest
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